In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCā€™s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eurofins Scientific SE

http://www.eurofins.com

Latest From Eurofins Scientific SE

Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

India Coronavirus COVID-19

Appointments: Basliea, BenevolentAI, OMEICOS, Recursion, Takeda UK And Bone Therapeutics Announce New Hires

New appointments have been announced this week by Basilea, BenevolentAI, OMEICOS Therapeutics, Pharnext, Recursion Pharmaceuticals, Sonde Health, Takeda UK, Bone Therapeutics and Glythera.

Executive Changes BioPharmaceutical

Will Eurofins Deal See Advinus Turn The Corner?

Eurofins Scientific has snapped up the contract research business of Advinus Therapeutics, continuing its ongoing acquisition momentum. The deal also ends long-running speculation around a potential sale of Advinus, amid its rocky recent run.

Commercial Deals

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings ā€“ totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) ā€“ showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics
See All

Company Information

  • Industry
  • Laboratory Testing Services
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register